Danaher (DHR) in Pivotal Point Check: Surprisingly Strong Quarterly Results in the Diagnostics Sector - Revenue Rises 4.4% to $6.05 Billion!
Reading Time: 2 minutes
Revenue and earnings significantly exceed expectations in Q3. The diagnostics segment was the main driver of growth. Management reaffirms the outlook for the fiscal year 2025. Danaher is a science and technology company based in the USA. The stock rose over 10% during the day but gave up gains by the market close. Nonetheless, the significant price increase is attributed to the release of Q3 2025 figures, which surpassed analysts' expectations. The diagnostics specialist announced that adjusted earnings per share for Q3 were $1.89....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
